Cargando…
Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens
Hepatitis A virus (HAV) is an emerging public health concern and there is an urgent need for ways to rapidly identify cases so that outbreaks can be managed effectively. Conventional testing for HAV relies on anti-HAV IgM seropositivity. However, studies estimate that 10–30% of patients may not be d...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777614/ https://www.ncbi.nlm.nih.gov/pubmed/35062362 http://dx.doi.org/10.3390/v14010159 |
_version_ | 1784637107975749632 |
---|---|
author | Kozak, Robert A. Rutherford, Candace Richard-Greenblatt, Melissa Chau, N. Y. Elizabeth Cabrera, Ana Biondi, Mia Borlang, Jamie Day, Jaqueline Osiowy, Carla Ramachandran, Sumathi Mayer, Nancy Glaser, Laurel Smieja, Marek |
author_facet | Kozak, Robert A. Rutherford, Candace Richard-Greenblatt, Melissa Chau, N. Y. Elizabeth Cabrera, Ana Biondi, Mia Borlang, Jamie Day, Jaqueline Osiowy, Carla Ramachandran, Sumathi Mayer, Nancy Glaser, Laurel Smieja, Marek |
author_sort | Kozak, Robert A. |
collection | PubMed |
description | Hepatitis A virus (HAV) is an emerging public health concern and there is an urgent need for ways to rapidly identify cases so that outbreaks can be managed effectively. Conventional testing for HAV relies on anti-HAV IgM seropositivity. However, studies estimate that 10–30% of patients may not be diagnosed by serology. Molecular assays that can directly detect viral nucleic acids have the potential to improve diagnosis, which is key to prevent the spread of infections. In this study, we developed a real-time PCR (RT-PCR) assay to detect HAV RNA for the identification of acute HAV infection. Primers were designed to target the conserved 5′-untranslated region (5′-UTR) of HAV, and the assay was optimized on both the Qiagen Rotor-Gene and the BD MAX. We successfully detected HAV from patient serum and stool samples with moderate differences in sensitivity and specificity depending on the platform used. Our results highlight the clinical utility of using a molecular assay to detect HAV from various specimen types that can be implemented in hospitals to assist with diagnostics, treatment and prevention. |
format | Online Article Text |
id | pubmed-8777614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87776142022-01-22 Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens Kozak, Robert A. Rutherford, Candace Richard-Greenblatt, Melissa Chau, N. Y. Elizabeth Cabrera, Ana Biondi, Mia Borlang, Jamie Day, Jaqueline Osiowy, Carla Ramachandran, Sumathi Mayer, Nancy Glaser, Laurel Smieja, Marek Viruses Article Hepatitis A virus (HAV) is an emerging public health concern and there is an urgent need for ways to rapidly identify cases so that outbreaks can be managed effectively. Conventional testing for HAV relies on anti-HAV IgM seropositivity. However, studies estimate that 10–30% of patients may not be diagnosed by serology. Molecular assays that can directly detect viral nucleic acids have the potential to improve diagnosis, which is key to prevent the spread of infections. In this study, we developed a real-time PCR (RT-PCR) assay to detect HAV RNA for the identification of acute HAV infection. Primers were designed to target the conserved 5′-untranslated region (5′-UTR) of HAV, and the assay was optimized on both the Qiagen Rotor-Gene and the BD MAX. We successfully detected HAV from patient serum and stool samples with moderate differences in sensitivity and specificity depending on the platform used. Our results highlight the clinical utility of using a molecular assay to detect HAV from various specimen types that can be implemented in hospitals to assist with diagnostics, treatment and prevention. MDPI 2022-01-15 /pmc/articles/PMC8777614/ /pubmed/35062362 http://dx.doi.org/10.3390/v14010159 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kozak, Robert A. Rutherford, Candace Richard-Greenblatt, Melissa Chau, N. Y. Elizabeth Cabrera, Ana Biondi, Mia Borlang, Jamie Day, Jaqueline Osiowy, Carla Ramachandran, Sumathi Mayer, Nancy Glaser, Laurel Smieja, Marek Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title | Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title_full | Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title_fullStr | Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title_full_unstemmed | Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title_short | Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens |
title_sort | development and evaluation of a molecular hepatitis a virus assay for serum and stool specimens |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777614/ https://www.ncbi.nlm.nih.gov/pubmed/35062362 http://dx.doi.org/10.3390/v14010159 |
work_keys_str_mv | AT kozakroberta developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT rutherfordcandace developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT richardgreenblattmelissa developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT chaunyelizabeth developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT cabreraana developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT biondimia developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT borlangjamie developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT dayjaqueline developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT osiowycarla developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT ramachandransumathi developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT mayernancy developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT glaserlaurel developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens AT smiejamarek developmentandevaluationofamolecularhepatitisavirusassayforserumandstoolspecimens |